Paul Bresge

Paul Bresge has been a leader in the cell and gene therapy biotech space for over a decade. He is co-founder and Chief Executive Officer at Ray Therapeutics, an optogenetics gene therapy company for blinding diseases. Prior to co-founding Ray Therapeutics, Mr. Bresge served as Chief Executive Officer at jCyte, a late-stage clinical cell therapy company developing a treatment for retinitis pigmentosa. He was involved with jCyte prior to its inception in 2012 and concluded a $252M licensing deal with Santen Pharmaceutical in 2020. In addition to his current role as CEO, Mr. Bresge is on the board of directors of Healios, an iPSC company with programs in ophthalmology and oncology, and is a mentor on the Winning Pitch Challenge. Mr. Bresge is passionate about supporting companies with emerging technologies that have great potential to address unmet needs for patients with blinding and other diseases.